Acquired Platelet Dysfunction

Hematology/Oncology Clinics of North America

Volumn 21, Issue 4, 2007, Pages 647-661

  Shen, Yu Min P ^a   Frenkel, Eugene P ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; ANTIBIOTIC AGENT; ANTITHROMBOCYTIC AGENT; APROTININ; CARDIOVASCULAR AGENT; CEPHALOSPORIN DERIVATIVE; CLOPIDOGREL; DESMOPRESSIN; ERYTHROPOIETIN; FIBRINOGEN; FIBRINOGEN DEGRADATION PRODUCT; FISH OIL; HERBACEOUS AGENT; ILOPROST; NITRIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; PHENOTHIAZINE DERIVATIVE; PROSTACYCLIN; PSYCHOTROPIC AGENT; THIENOPYRIDINE; TICLOPIDINE; TIROFIBAN; TRANEXAMIC ACID; TURMERIC; UNCLASSIFIED DRUG; UNINDEXED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ALCOHOL CONSUMPTION; ANTIGEN BINDING; BLEEDING TENDENCY; BLEEDING TIME; CARDIOPULMONARY BYPASS; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CRYOPRECIPITATE; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; ERYTHROCYTE TRANSFUSION; GASTROINTESTINAL TOXICITY; HEMODIALYSIS; HUMAN; LIVER DISEASE; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PARAPROTEINEMIA; PATHOGENESIS; PERITONEAL DIALYSIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; THROMBOCYTE RELEASE REACTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; THROMBOSIS; UREMIA;

BLOOD PLATELET DISORDERS; CARDIOPULMONARY BYPASS; DISEASE; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 34547098364     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.06.001     Document Type: Review

References (114)

1. Remuzzi G., Perico N., Zoja C., et al. Role of endothelium-derived nitric oxide in the bleeding tendency of uremia. J Clin Invest 86 5 (1990) 1768-1771
2. Noris M., Benigni A., Boccardo P., et al. Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. Kidney Int 44 2 (1993) 445-450
3. Escolar G., Cases A., Bastida E., et al. Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein IIb-IIIa. Blood 76 7 (1990) 1336-1340
4. Gralnick H.R., McKeown L.P., Williams S.B., et al. Plasma and platelet von Willebrand factor defects in uremia. Am J Med 85 6 (1988) 806-810
5. Salvati F., and Liani M. Role of platelet surface receptor abnormalities in the bleeding and thrombotic diathesis of uremic patients on hemodialysis and peritoneal dialysis. Int J Artif Organs 24 3 (2001) 131-135
6. Yoshida E., Fujimura Y., Ikeda Y., et al. Impaired high-shear-stress-induced platelet aggregation in patients with chronic renal failure undergoing haemodialysis. Br J Haematol 89 4 (1995) 861-867
7. Di Minno G., Martinez J., McKean M.L., et al. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med 79 5 (1985) 552-559
8. Escolar G., Diaz-Ricart M., Cases A., et al. Abnormal cytoskeletal assembly in platelets from uremic patients. Am J Pathol 143 3 (1993) 823-831
9. Vlachoyannis J., and Schoeppe W. Adenylate cyclase activity and cAMP content of human platelets in uraemia. Eur J Clin Invest 12 5 (1982) 379-381
10. Sreedhara R., Itagaki I., Lynn B., et al. Defective platelet aggregation in uremia is transiently worsened by hemodialysis. Am J Kidney Dis 25 4 (1995) 555-563
11. Campistol J.M., Cofan F., Diaz Ricart M., et al. Correction of uremic platelet dysfunction after renal transplantation. Transplant Proc 27 4 (1995) 2244-2245
12. Cases A., Escolar G., Reverter J.C., et al. Recombinant human erythropoietin treatment improves platelet function in uremic patients. Kidney Int 42 3 (1992) 668-672
13. Moia M., Mannucci P.M., Vizzotto L., et al. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 2 8570 (1987) 1227-1229
14. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ 300 6724 (1990) 573-578
15. Janson P.A., Jubelirer S.J., Weinstein M.J., et al. Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med 303 23 (1980) 1318-1322
16. Mannucci P.M., Remuzzi G., Pusineri F., et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 308 1 (1983) 8-12
17. Zeigler Z.R., Megaludis A., and Fraley D.S. Desmopressin (d-DAVP) effects on platelet rheology and von Willebrand factor activities in uremia. Am J Hematol 39 2 (1992) 90-95
18. Livio M., Mannucci P.M., Vigano G., et al. Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med 315 12 (1986) 731-735
19. Jacobs P., Jacobson J., and Kahn D. Perioperative administration of a single dose of conjugated oestrogen to uraemic patients is ineffective in improving haemostasis. Am J Hematol 46 1 (1994) 24-28
20. Thomas D.P., Ream V.J., and Stuart R.K. Platelet aggregation in patients with Laennec's cirrhosis of the liver. N Engl J Med 276 24 (1967) 1344-1348
21. Cowan D.H. Effect of alcoholism on hemostasis. Semin Hematol 17 2 (1980) 137-147
22. Mammen E.F. Coagulopathies of liver disease. Clin Lab Med 14 4 (1994) 769-780
23. Mannucci P.M., Vicente V., Vianello L., et al. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood 67 4 (1986) 1148-1153
24. Robert F., Mignucci M., McCurdy S.A., et al. Hemostatic abnormalities associated with monoclonal gammopathies. Am J Med Sci 306 6 (1993) 359-366
25. Rozenberg M.C., and Dintenfass L. Platelet aggregation in Waldenstrom's macroglobulinaemia. Thromb Diath Haemorrh 14 1-2 (1965) 202-208
26. Wallace M.R., Simon S.R., Ershler W.B., et al. Hemorrhagic diathesis in multiple myeloma. Acta Haematol 72 5 (1984) 340-342
27. Vigliano E.M., and Horowitz H.I. Bleeding syndrome in a patient with IgA myeloma: interaction of protein and connective tissue. Blood 29 6 (1967) 823-836
28. McGrath K.M., Stuart J.J., and Richards II F. Correlation between serum IgG, platelet membrane IgG, and platelet function in hypergammaglobulinaemic states. Br J Haematol 42 4 (1979) 585-591
29. DiMinno G., Coraggio F., Cerbone A.M., et al. A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest 77 1 (1986) 157-164
30. Waddell C.C., Brown J.A., and Repinecz Y.A. Abnormal platelet function in myeloproliferative disorders. Arch Pathol Lab Med 105 8 (1981) 432-435
31. Tinggaard Pedersen N., and Laursen B. Megakaryocytes in cubital venous blood in patients with chronic myeloproliferative diseases. Scand J Haematol 30 1 (1983) 50-58
32. Berndt M.C., Kabral A., Grimsley P., et al. An acquired Bernard-Soulier-like platelet defect associated with juvenile myelodysplastic syndrome. Br J Haematol 68 1 (1988) 97-101
33. Caranobe C., Sie P., Fernandez F., et al. Abnormal platelet serotonin uptake and binding sites in myeloproliferative disorders. Thromb Haemost 51 3 (1984) 349-353
34. Kaplan R., Gabbeta J., Sun L., et al. Combined defect in membrane expression and activation of platelet GPIIb-IIIa complex without primary sequence abnormalities in myeloproliferative disease. Br J Haematol 111 3 (2000) 954-964
35. Moore A., and Nachman R.L. Platelet Fc receptor. Increased expression in myeloproliferative disease. J Clin Invest 67 4 (1981) 1064-1071
36. Okuma M., Takayama H., and Uchino H. Subnormal platelet response to thromboxane A2 in a patient with chronic myeloid leukaemia. Br J Haematol 51 3 (1982) 469-477
37. Takayama H., Okuma M., Kanaji K., et al. Altered arachidonate metabolism by leukocytes and platelets in myeloproliferative disorders. Prostaglandins Leukot Med 12 3 (1983) 261-272
38. Boneu B., Nouvel C., Sie P., et al. Platelets in myeloproliferative disorders. I. A comparative evaluation with certain platelet function tests. Scand J Haematol 25 3 (1980) 214-220
39. Lopez-Fernandez M.F., Lopez-Berges C., Martin R., et al. Abnormal structure of von Willebrand factor in myeloproliferative syndrome is associated to either thrombotic or bleeding diathesis. Thromb Haemost 58 2 (1987) 753-757
40. Castaman G., Rodeghiero F., Lattuada A., et al. Multimeric pattern of plasma and platelet von Willebrand factor is normal in uremic patients. Am J Hematol 44 4 (1993) 266-269
41. Budde U., Dent J.A., Berkowitz S.D., et al. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood 68 6 (1986) 1213-1217
42. Manoharan A., Gemmell R., Brighton T., et al. Thrombosis and bleeding in myeloproliferative disorders: identification of at-risk patients with whole blood platelet aggregation studies. Br J Haematol 105 3 (1999) 618-625
43. Thiele J., Quitmann H., Wagner S., et al. Dysmegakaryopoiesis in myelodysplastic syndromes (MDS): an immunomorphometric study of bone marrow trephine biopsy specimens. J Clin Pathol 44 4 (1991) 300-305
44. Wong K.F., and Chan J.K. Are 'dysplastic' and hypogranular megakaryocytes specific markers for myelodysplastic syndrome?. Br J Haematol 77 4 (1991) 509-514
45. Widell S., and Hast R. Balloon-like platelets in myelodysplastic syndromes-a feature of dysmegakaryopoiesis?. Leuk Res 11 8 (1987) 747-752
46. Gerrard J.M., and McNicol A. Platelet storage pool deficiency, leukemia, and myelodysplastic syndromes. Leuk Lymphoma 8 4-5 (1992) 277-281
47. Pamphilon D.H., Aparicio S.R., Roberts B.E., et al. The myelodysplastic syndromes-a study of haemostatic function and platelet ultrastructure. Scand J Haematol 33 5 (1984) 486-491
48. George J.N. Platelet IgG: measurement, interpretation, and clinical significance. Prog Hemost Thromb 10 (1991) 97-126
49. Stuart M.J., Kelton J.G., and Allen J.B. Abnormal platelet function and arachidonate metabolism in chronic idiopathic thrombocytopenic purpura. Blood 58 2 (1981) 326-329
50. George J.N., el-Harake M.A., and Raskob G.E. Chronic idiopathic thrombocytopenic purpura. N Engl J Med 331 18 (1994) 1207-1211
51. Devine D.V., Currie M.S., Rosse W.F., et al. Pseudo-Bernard-Soulier syndrome: thrombocytopenia caused by autoantibody to platelet glycoprotein Ib. Blood 70 2 (1987) 428-431
52. Dromigny A., Triadou P., Lesavre P., et al. Lack of platelet response to collagen associated with autoantibodies against glycoprotein (GP) Ia/IIa and Ib/IX leading to the discovery of SLE. Hematol Cell Ther 38 4 (1996) 355-357
53. Dorsch C.A., and Meyerhoff J. Mechanisms of abnormal platelet aggregation in systemic lupus erythematosus. Arthritis Rheum 25 8 (1982) 966-973
54. Heyns A.D., Fraser J., and Retief F.P. Platelet aggregation in chronic idiopathic thrombocytopenic purpura. J Clin Pathol 31 12 (1978) 1239-1243
55. Handagama P.J., George J.N., Shuman M.A., et al. Incorporation of a circulating protein into megakaryocyte and platelet granules. Proc Natl Acad Sci U S A 84 3 (1987) 861-865
56. Weiss H.J., Rosove M.H., Lages B.A., et al. Acquired storage pool deficiency with increased platelet-associated IgG. Report of five cases. Am J Med 69 5 (1980) 711-717
57. Pareti F.I., Capitanio A., Mannucci L., et al. Acquired dysfunction due to the circulation of "exhausted" platelets. Am J Med 69 2 (1980) 235-240
58. Solum N.O., Rigollot C., Budzynski A.Z., et al. A quantitative evaluation of the inhibition of platelet aggregation by low molecular weight degradation products of fibrinogen. Br J Haematol 24 4 (1973) 419-434
59. Beurling-Harbury C., and Galvan C.A. Acquired decrease in platelet secretory ADP associated with increased postoperative bleeding in post-cardiopulmonary bypass patients and in patients with severe valvular heart disease. Blood 52 1 (1978) 13-23
60. Harker L.A., Malpass T.W., Branson H.E., et al. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 56 5 (1980) 824-834
61. Khuri S.F., Wolfe J.A., Josa M., et al. Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss. J Thorac Cardiovasc Surg 104 1 (1992) 94-107
62. McKenna R., Bachmann F., Whittaker B., et al. The hemostatic mechanism after open-heart surgery. II. Frequency of abnormal platelet functions during and after extracorporeal circulation. J Thorac Cardiovasc Surg 70 2 (1975) 298-308
63. Woodman R.C., and Harker L.A. Bleeding complications associated with cardiopulmonary bypass. Blood 76 9 (1990) 1680-1697
64. Abrams C.S., Ellison N., Budzynski A.Z., et al. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 75 1 (1990) 128-138
65. George J.N., Pickett E.B., Saucerman S., et al. Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J Clin Invest 78 2 (1986) 340-348
66. Gluszko P., Rucinski B., Musial J., et al. Fibrinogen receptors in platelet adhesion to surfaces of extracorporeal circuit. Am J Physiol 252 3 Pt 2 (1987) H615-H621
67. Lindon J.N., McManama G., Kushner L., et al. Does the conformation of adsorbed fibrinogen dictate platelet interactions with artificial surfaces?. Blood 68 2 (1986) 355-362
68. Kestin A.S., Valeri C.R., Khuri S.F., et al. The platelet function defect of cardiopulmonary bypass. Blood 82 1 (1993) 107-117
69. Khuri S.F., Valeri C.R., Loscalzo J., et al. Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass. Ann Thorac Surg 60 4 (1995) 1008-1014
70. Weksler B.B., Pett S.B., Alonso D., et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 308 14 (1983) 800-805
71. Hackmann T., Gascoyne R.D., Naiman S.C., et al. A trial of desmopressin (1-desamino-8-D-arginine vasopressin) to reduce blood loss in uncomplicated cardiac surgery. N Engl J Med 321 21 (1989) 1437-1443
72. Seear M.D., Wadsworth L.D., Rogers P.C., et al. The effect of desmopressin acetate (DDAVP) on postoperative blood loss after cardiac operations in children. J Thorac Cardiovasc Surg 98 2 (1989) 217-219
73. Fish K.J., Sarnquist F.H., van Steennis C., et al. A prospective, randomized study of the effects of prostacyclin on platelets and blood loss during coronary bypass operations. J Thorac Cardiovasc Surg 91 3 (1986) 436-442
74. Walker I.D., Davidson J.F., Faichney A., et al. A double blind study of prostacyclin in cardiopulmonary bypass surgery. Br J Haematol 49 3 (1981) 415-423
75. Hardy J.F., and Desroches J. Natural and synthetic antifibrinolytics in cardiac surgery. Can J Anaesth 39 4 (1992) 353-365
76. van Oeveren W., Harder M.P., Roozendaal K.J., et al. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 99 5 (1990) 788-796 [discussion: 796-7]
77. Roth G.J., and Majerus P.W. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 56 3 (1975) 624-632
78. Hirsh J., Dalen J.E., Fuster V., et al. Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects. Chest 108 Suppl 4 (1995) 247S-257S
79. Dalen J.E. Aspirin resistance: is it real? Is it clinically significant?. Am J Med 120 1 (2007) 1-4
80. Weiss H.J., Tschopp T.B., and Baumgartner H.R. Impaired interaction (adhesion-aggregation) of platelets with the subendothelium in storage-pool disease and after aspirin ingestion. A comparison with von Willebrand's disease. N Engl J Med 293 13 (1975) 619-623
81. Cronberg S., Wallmark E., and Soderberg I. Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans. Scand J Haematol 33 2 (1984) 155-159
82. Roderick P.J., Wilkes H.C., and Meade T.W. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol 35 3 (1993) 219-226
83. Schafer A.I. Effects of nonsteroidal anti-inflammatory therapy on platelets. Am J Med 106 5B (1999) 25S-36S
84. Kennedy B.M. Aspirin and surgery-a review. Ir Med J 77 11 (1984) 363-369
85. Kobrinsky N.L., Israels E.D., Gerrard J.M., et al. Shortening of bleeding time by 1-deamino-8-D-arginine vasopressin in various bleeding disorders. Lancet 1 8387 (1984) 1145-1148
86. Simon L.S., and Mills J.A. Nonsteroidal antiinflammatory drugs (second of two parts). N Engl J Med 302 22 (1980) 1237-1243
87. Thomas P., Hepburn B., Kim H.C., et al. Nonsteroidal anti-inflammatory drugs in the treatment of hemophilic arthropathy. Am J Hematol 12 2 (1982) 131-137
88. Claria J. Cyclooxygenase-2 biology. Curr Pharm Des 9 27 (2003) 2177-2190
89. McTavish D., Faulds D., and Goa K.L. Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 40 2 (1990) 238-259
90. Leon M.B., Baim D.S., Popma J.J., et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 339 23 (1998) 1665-1671
91. Jantzen H.M., Gousset L., Bhaskar V., et al. Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation. Thromb Haemost 81 1 (1999) 111-117
92. Hardisty R.M., Powling M.J., and Nokes T.J. The action of ticlopidine on human platelets. Studies on aggregation, secretion, calcium mobilization and membrane glycoproteins. Thromb Haemost 64 1 (1990) 150-155
93. Sattler F.R., Weitekamp M.R., and Ballard J.O. Potential for bleeding with the new beta-lactam antibiotics. Ann Intern Med 105 6 (1986) 924-931
94. Shattil S.J., Bennett J.S., McDonough M., et al. Carbenicillin and penicillin G inhibit platelet function in vitro by impairing the interaction of agonists with the platelet surface. J Clin Invest 65 2 (1980) 329-337
95. Sunakawa K., Akita H., Iwata S., et al. Effects of antibiotics on platelet aggregation. Drugs 35 Suppl 2 (1988) 205-207
96. Lefkovits J., Plow E.F., and Topol E.J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 332 23 (1995) 1553-1559
97. George J.N., Caen J.P., and Nurden A.T. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 75 7 (1990) 1383-1395
98. Berkowitz S.D., Sane D.C., Sigmon K.N., et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J Am Coll Cardiol 32 2 (1998) 311-319
99. Ferguson J.J., Kereiakes D.J., Adgey A.A., et al. Safe use of platelet GP IIb/IIIa inhibitors. Am Heart J 135 4 (1998) S77-S89
100. Schafer A.I., Alexander R.W., and Handin R.I. Inhibition of platelet function by organic nitrate vasodilators. Blood 55 4 (1980) 649-654
101. Leon R., Tiarks C.Y., and Pechet L. Some observations on the in vivo effect of propranolol on platelet aggregation and release. Am J Hematol 5 2 (1978) 117-121
102. Barnathan E.S., Addonizio V.P., and Shattil S.J. Interaction of verapamil with human platelet alpha-adrenergic receptors. Am J Physiol 242 1 (1982) H19-H23
103. Fujinishi A., Takahara K., Ohba C., et al. Effects of nisoldipine on cytosolic calcium, platelet aggregation, and coagulation/fibrinolysis in patients with coronary artery disease. Angiology 48 6 (1997) 515-521
104. Ring M.E., Corrigan Jr. J.J., and Fenster P.E. Effects of oral diltiazem on platelet function: alone and in combination with "low dose" aspirin. Thromb Res 44 3 (1986) 391-400
105. Lawson D., Mehta J., Mehta P., et al. Cumulative effects of quinidine and aspirin on bleeding time and platelet alpha 2-adrenoceptors: potential mechanism of bleeding diathesis in patients receiving this combination. J Lab Clin Med 108 6 (1986) 581-586
106. Jain M.K., Eskow K., Kuchibhotla J., et al. Correlation of inhibition of platelet aggregation by phenothiazines and local anesthetics with their effects on a phospholipid bilayer. Thromb Res 13 6 (1978) 1067-1075
107. Morishita S., Aoki S., and Watanabe S. Different effect of desipramine on protein kinase C in platelets between bipolar and major depressive disorders. Psychiatry Clin Neurosci 53 1 (1999) 11-15
108. Pai V.B., and Kelly M.W. Bruising associated with the use of fluoxetine. Ann Pharmacother 30 7-8 (1996) 786-788
109. Leaf A., and Weber P.C. Cardiovascular effects of n-3 fatty acids. N Engl J Med 318 9 (1988) 549-557
110. Apitz-Castro R., Escalante J., Vargas R., et al. Ajoene, the antiplatelet principle of garlic, synergistically potentiates the antiaggregatory action of prostacyclin, forskolin, indomethacin and dypiridamole on human platelets. Thromb Res 42 3 (1986) 303-311
111. Hammerschmidt D.E. Szechwan purpura. N Engl J Med 302 21 (1980) 1191-1193
112. Srivastava K.C. Onion exerts antiaggregatory effects by altering arachidonic acid metabolism in platelets. Prostaglandins Leukot Med 24 1 (1986) 43-50
113. Srivastava K.C. Extracts from two frequently consumed spices-cumin (Cuminum cyminum) and turmeric (Curcuma longa)-inhibit platelet aggregation and alter eicosanoid biosynthesis in human blood platelets. Prostaglandins Leukot Essent Fatty Acids 37 1 (1989) 57-64
114. Inhibitory effect of Ginkgo biloba extract on human platelet aggregation. Platelets 10 5 (1999) 298-305